Drug repurposing against pneumococcus and other Streptococcus genus species

Summary of the technology

CSIC has developed a patent for the use of 7 drugs as novel antimicrobials that display bactericidal activity against Streptococcus pneumoniae (pneumococcus), acting on therapeutic targets not considered in the usual treatments for this pathogen.

Industrial partners are sought which are interested in patent licensing for the development of the mentioned drugs as antibacterials targeting the Streptococcus genus and that open up new ways for treatments against these pathogens and for combating current antibiotic resistance issues.

CSIC - Consejo Superior de Investigaciones Científicas

Details of the Technology Offer

A new antipneumococcal treatment to combat antibiotic resistance Pneumococcus is a human pathogen causing important diseases such as pneumonia, sepsis and meningitis. This organism is a major infectious agent responsible of more than a million deaths a year worldwide, with the highest incidence on people under 5 and over 65 years old. Vaccination provides an insufficient protection due to the high serotype variety of this bacterium leading to serotype replacement phenomena.

On the other hand, in the last years, a notable increase has been observed in clinical pneumococcal strains resistant to traditional antibiotics, making it necessary the search for alternative treatments to combat this pathogen. The compounds developed here are drugs selected from the screening of a commercial library, but without any activity against pneumococcus previously described. All of them display analogous chemical features and act by a similar molecular mechanism.

Effect of compounds on pneumococcal growth curve in planktonic cultures

Main innovations and advantages

· The entry of these compounds in clinical phases would be favoured as they are drugs already approved by international medicines agencies, so data on their pharmacodynamics, pharmacokinetics and toxicity are widely known.
· Appearance of resistances against these compounds is highly unlikely, since their action mechanism is different to that of traditional antibiotics.

Intellectual property status

  • Granted Patent
  • Patent application number :-

Related Keywords

  • Medicine, Human Health
  • Virus, Virology / Antibiotics / Bacteriology
  • Health care
  • Medical/health

About CSIC - Consejo Superior de Investigaciones Científicas

The Spanish National Research Council (in Spanish 'Consejo Superior de Investigaciones Científicas (CSIC)') is a government agency for basic and applied scientific research.

It is the largest public research organization in Spain, with presence in all the Autonomous Communities through 126 centers and 145 associated units.

CSIC - Consejo Superior de Investigaciones Científicas

Never miss an update from CSIC - Consejo Superior de Investigaciones Científicas

Create your free account to connect with CSIC - Consejo Superior de Investigaciones Científicas and thousands of other innovative organizations and professionals worldwide

CSIC - Consejo Superior de Investigaciones Científicas

Send a request for information
to CSIC - Consejo Superior de Investigaciones Científicas

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support